

Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Prevalence

Journal of the National Cancer Institute

99, 1484-1489

DOI: [10.1093/jnci/djm153](https://doi.org/10.1093/jnci/djm153)

Citation Report

#	ARTICLE	IF	CITATIONS
2	What is low-risk prostate cancer and what is its natural history?. World Journal of Urology, 2008, 26, 415-422.	1.2	27
3	The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate, 2008, 68, 985-993.	1.2	67
4	The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU International, 2008, 102, 1068-1073.	1.3	38
5	Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. BMC Medicine, 2008, 6, 6.	2.3	95
6	The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. European Urology, 2008, 54, 581-588.	0.9	100
7	Re: Saturation Prostate Needle Biopsy and Prostate Cancer Detection at Initial and Repeat Evaluation. European Urology, 2008, 54, 688-690.	0.9	0
8	Association of Prostate Cancer and Manganese Superoxide Dismutase AA Genotype Influenced by Presence of Occult Cancer in Control Group. Urology, 2008, 72, 238-241.	0.5	17
10	Evaluation of Prostatitis in Autopsied Prostates—Is Chronic Inflammation More Associated With Benign Prostatic Hyperplasia or Cancer?. Journal of Urology, 2008, 179, 1736-1740.	0.2	106
11	It's Time to Abandon an Upper Limit of Normal for Prostate Specific Antigen: Assessing the Risk of Prostate Cancer. Journal of Urology, 2008, 180, 1219-1222.	0.2	17
13	Prostate Cancers Diagnosed at Repeat Biopsy are Smaller and Less Likely to be High Grade. Journal of Urology, 2008, 180, 1325-1329.	0.2	58
14	Against Diagnosis. Annals of Internal Medicine, 2008, 149, 200.	2.0	58
15	Ultrasonic tissue-type imaging of the prostate: Implications for biopsy and treatment guidance. Cancer Biomarkers, 2008, 4, 201-212.	0.8	34
16	Saturation biopsies for prostate cancer: current uses and future prospects. Nature Reviews Urology, 2009, 6, 645-652.	1.9	34
17	Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen. Prostate Cancer and Prostatic Diseases, 2009, 12, 137-142.	2.0	10
18	Utility of a 3-Dimensional Transrectal Ultrasound-guided Prostate Biopsy System for Prostate Cancer Detection. Technology in Cancer Research and Treatment, 2009, 8, 99-103.	0.8	5
19	Saturation Biopsy of the Prostate: Why Saturation Does Not Saturate. European Urology, 2009, 56, 619-621.	0.9	26
22	Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level. Cancer Science, 2009, 100, 1880-1884.	1.7	15
23	Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU International, 2009, 103, 49-54.	1.3	57

#	ARTICLE	IF	CITATIONS
24	Predicting tumour location in radical prostatectomy specimens: same-patient comparisons of 21-sample versus sextant biopsy. <i>BJU International</i> , 2009, 104, 616-620.	1.3	9
25	Evaluating the cancer detection and grading potential of prostatic-zinc imaging: a simulation study. <i>Physics in Medicine and Biology</i> , 2009, 54, 781-796.	1.6	16
26	Pathological Characteristics of Prostate Cancer in Elderly Men. <i>Journal of Urology</i> , 2009, 182, 927-930.	0.2	32
27	Optimizing Prostate Cancer Detection: 8 Versus 12-Core Biopsy Protocol. <i>Journal of Urology</i> , 2009, 182, 1329-1336.	0.2	40
28	The Role of Prostate Specific Membrane Antigen and Pepsinogen C Tissue Expression as an Adjunctive Method to Prostate Cancer Diagnosis. <i>Journal of Urology</i> , 2009, 181, 594-600.	0.2	16
29	Management of rising prostate-specific antigen following a negative biopsy. <i>Current Opinion in Urology</i> , 2010, 20, 198-203.	0.9	7
30	Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. <i>European Urology</i> , 2010, 58, 851-864.	0.9	96
31	Markers for Detection of Prostate Cancer. <i>Cancers</i> , 2010, 2, 1125-1154.	1.7	39
32	Metabolomic Imaging for Human Prostate Cancer Detection. <i>Science Translational Medicine</i> , 2010, 2, 16ra8.	5.8	44
33	Effect of the number of biopsy cores on prostate cancer detection and staging. <i>Future Oncology</i> , 2010, 6, 381-390.	1.1	12
34	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. <i>BMJ: British Medical Journal</i> , 2010, 341, c4521-c4521.	2.4	195
35	Prostate Cancer: To Screen or Not to Screen?. <i>Urologic Clinics of North America</i> , 2010, 37, 1-9.	0.8	13
36	Importance of Additional "Extreme" Anterior Apical Needle Biopsies in the Initial Detection of Prostate Cancer. <i>Urology</i> , 2010, 75, 1034-1039.	0.5	90
37	Biopsy Schemes with the Fewest Cores for Detecting 95% of the Prostate Cancers Detected by a 24-Core Biopsy. <i>European Urology</i> , 2010, 57, 1-8.	0.9	94
41	Management of low (favourable)-risk prostate cancer. <i>BJU International</i> , 2011, 108, 1684-1695.	1.3	27
42	Management of Rising Prostate-specific Antigen After a Negative Biopsy. <i>Current Urology Reports</i> , 2011, 12, 197-202.	1.0	19
43	Prediction of Erectile Function Following Treatment for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1205.	3.8	253
44	Urine <i>TMPRSS2:ERG</i> Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. <i>Science Translational Medicine</i> , 2011, 3, 94ra72.	5.8	313

#	ARTICLE	IF	CITATIONS
45	Optimization of PSA Screening Policies. <i>Medical Decision Making</i> , 2012, 32, 337-349.	1.2	41
46	Optimization of Prostate Biopsy Referral Decisions. <i>Manufacturing and Service Operations Management</i> , 2012, 14, 529-547.	2.3	72
47	Investigation of Optimal Prostate Biopsy Schemes for Chinese Patients with Different Clinical Characteristics. <i>Urologia Internationalis</i> , 2012, 89, 425-432.	0.6	4
48	Simulation optimization of PSA-threshold based prostate cancer screening policies. <i>Health Care Management Science</i> , 2012, 15, 293-309.	1.5	22
49	Toward the End of Blind Prostate Biopsies?. <i>European Urology</i> , 2012, 62, 997-998.	0.9	5
50	The Impact of Real-Time Elastography Guiding a Systematic Prostate Biopsy to Improve Cancer Detection Rate: A Prospective Study of 353 Patients. <i>Journal of Urology</i> , 2012, 187, 2039-2043.	0.2	103
52	Prostate Sampling by 12-Core Biopsy: Comparison of the Biopsy Results With Tumor Location in Prostatectomy Specimens. <i>Urology</i> , 2012, 79, 37-42.	0.5	37
53	Editorial Comment. <i>Journal of Urology</i> , 2012, 188, 767-768.	0.2	1
54	Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. <i>Prostate</i> , 2012, 72, 108-115.	1.2	22
55	Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC Map: A prospective large-scale cohort study. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 1414-1421.	1.9	47
56	The clinical, research, and social value of autopsy after any cancer death. <i>Cancer</i> , 2012, 118, 3002-3009.	2.0	18
57	Screening for Prostate Cancer: Early Detection or Overdetection?. <i>Annual Review of Medicine</i> , 2012, 63, 161-170.	5.0	43
58	Re: Role of Magnetic Resonance Imaging Before Initial Biopsy: Comparison of Magnetic Resonance Imaging-Targeted and Systematic Biopsy for Significant Prostate Cancer Detection. <i>European Urology</i> , 2012, 61, 622-623.	0.9	5
59	Re: A Prospective, Randomized Pilot Study Evaluating the Effects of Metformin and Lifestyle Intervention on Patients With Prostate Cancer Receiving Androgen Deprivation Therapy. <i>European Urology</i> , 2012, 61, 623-624.	0.9	5
60	Transrectal sonoelastography in the detection of prostate cancers: a meta-analysis. <i>BJU International</i> , 2012, 110, E614-20.	1.3	20
61	Prebiopsy Magnetic Resonance Imaging and Prostate Cancer Detection: Comparison of Random and Targeted Biopsies. <i>Journal of Urology</i> , 2013, 189, 493-499.	0.2	248
62	Screening for Prostate Cancer. , 2013, , 333-346.		2
63	Targeted biopsy based on ADC map in the detection and localization of prostate cancer: A feasibility study. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 1168-1177.	1.9	24

#	ARTICLE	IF	CITATIONS
64	Quantitative Ultrasound in Soft Tissues. , 2013, , .		137
66	Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 2013, 109, 641-650.	2.9	117
67	Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care. European Urology, 2013, 63, 214-230.	0.9	214
68	Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. European Journal of Cancer, 2013, 49, 3041-3048.	1.3	12
69	Optimization of Initial Prostate Biopsy in Clinical Practice: Sampling, Labeling and Specimen Processing. Journal of Urology, 2013, 189, 2039-2046.	0.2	173
71	Defining the threshold for significant versus insignificant prostate cancer. Nature Reviews Urology, 2013, 10, 473-482.	1.9	98
72	TMPRSS2-ERG Fusion Transcripts in Matched Urine and Needle Rinse Material after Biopsy for the Detection of Prostate Cancer. Clinical Chemistry, 2013, 59, 245-251.	1.5	10
73	Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. Journal of the National Cancer Institute, 2013, 105, 1050-1058.	3.0	208
74	Biópsia prostática orientada por fusão de imagem RMN-ETR: breve revisão a propósito de caso clínico. Acta Urológica Portuguesa, 2014, 31, 88-91.	0.1	0
75	Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. Experimental Biology and Medicine, 2014, 239, 805-812.	1.1	2
76	A Simple Schema for Informed Decision Making About Prostate Cancer Screening. Annals of Internal Medicine, 2014, 161, 441.	2.0	25
77	Interpretation of PSA levels after radical therapy for prostate cancer. Trends in Urology & Men's Health, 2014, 5, 30-34.	0.2	7
78	Overdetection in screening for prostate cancer. Current Opinion in Urology, 2014, 24, 256-263.	0.9	36
79	Real-Time Elastography in the Diagnosis of Patients Suspected of Having Prostate Cancer: A Meta-analysis. Ultrasound in Medicine and Biology, 2014, 40, 1400-1407.	0.7	43
80	Agreement of Gleason Score on Prostate Biopsy and Radical Prostatectomy Specimen: Is There Improvement With Increased Number of Biopsy Cylinders and the 2005 Revised Gleason Scoring?. Clinical Genitourinary Cancer, 2014, 12, 160-166.	0.9	14
81	Prostate cancer: the need for biomarkers and new therapeutic targets. Journal of Zhejiang University: Science B, 2014, 15, 16-42.	1.3	26
82	Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis. Tumor Biology, 2014, 35, 2157-2166.	0.8	11
83	Overdiagnosis and Overtreatment of Prostate Cancer. European Urology, 2014, 65, 1046-1055.	0.9	709

#	ARTICLE	IF	CITATIONS
84	Re: Prostate Biopsy for the Interventional Radiologist. <i>Journal of Urology</i> , 2014, 192, 765-767.	0.2	0
85	High Prevalence of Screen Detected Prostate Cancer in West Africans: Implications for Racial Disparity of Prostate Cancer. <i>Journal of Urology</i> , 2014, 192, 730-736.	0.2	46
86	Optimization of Prostate Biopsy. <i>Urologic Clinics of North America</i> , 2014, 41, 299-313.	0.8	79
87	Prostate Biopsy for the Interventional Radiologist. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 675-684.	0.2	15
88	Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. <i>Endocrine-Related Cancer</i> , 2014, 21, L17-L21.	1.6	34
89	The ONCOTYROL Prostate Cancer Outcome and Policy Model. <i>Medical Decision Making</i> , 2015, 35, 758-772.	1.2	8
92	Can multiparametric MRI rule in or rule out significant prostate cancer?. <i>Current Opinion in Urology</i> , 2015, 25, 490-497.	0.9	1
93	A prospective comparison of MRIâ€US fused targeted biopsy versus systematic ultrasoundâ€guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 220-225.	1.9	82
94	Assessment of longâ€term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. <i>Cancer</i> , 2015, 121, 4071-4079.	2.0	28
95	Preoperative erectile function and the pathologic features of prostate cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2015, 41, 265-273.	0.7	2
96	Investigating the ability of multiparametric MRI to exclude significant prostate cancer prior to transperineal biopsy. <i>Canadian Urological Association Journal</i> , 2015, 9, 853.	0.3	23
97	Association of MnSOD AA Genotype with the Progression of Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0131325.	1.1	14
98	Detecting Prostate Cancer. <i>Deutsches A&#x0308;rztblatt International</i> , 2015, 112, 605-11.	0.6	15
99	Prostate Cancer Diagnosis Using MR/Ultrasoundâ€Fusion Guided Biopsy. <i>JAMA Oncology</i> , 2015, 1, 831.	3.4	0
100	Focal therapy for prostate cancer: The current status. <i>Prostate International</i> , 2015, 3, 35-41.	1.2	61
101	Prediction of Significant Prostate Cancer at Prostate Biopsy and Per Core Detection Rate of Targeted and Systematic Biopsies Using Real-Time Shear Wave Elastography. <i>Urologia Internationalis</i> , 2015, 95, 189-196.	0.6	23
102	Imaging the Prostate with Quantitative Ultrasound: Implications for Guiding Biopsies, Targeting Focal Treatment, and Monitoring Therapy. , 2015, , 147-161.		1
103	When prostate cancer remains undetectable: The dilemma. <i>Turk Uroloji Dergisi</i> , 2015, 41, 32-38.	0.4	0

#	ARTICLE	IF	CITATIONS
104	Re: Relative Value of Race, Family History and Prostate Specific Antigen as Indications for Early Initiation of Prostate Cancer Screening. <i>Journal of Urology</i> , 2015, 193, 1063-1065.	0.2	3
105	Prevalence of incidental prostate cancer: A systematic review of autopsy studies. <i>International Journal of Cancer</i> , 2015, 137, 1749-1757.	2.3	293
106	Computer-Aided Detection and diagnosis for prostate cancer based on mono and multi-parametric MRI: A review. <i>Computers in Biology and Medicine</i> , 2015, 60, 8-31.	3.9	270
108	Computer-aided transrectal ultrasound: does prostate HistoScanning [®] improve detection performance of prostate cancer in repeat biopsies?. <i>BMC Urology</i> , 2015, 15, 76.	0.6	5
109	Gleason 6 Prostate Cancer: Translating Biology into Population Health. <i>Journal of Urology</i> , 2015, 194, 626-634.	0.2	75
110	Characteristics of undetected prostate cancer on diffusion-weighted MR Imaging at 3-Tesla with a b-value of 2000s/mm ² : Imaging-pathologic correlation. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 923-929.	1.8	12
111	Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study. <i>BJU International</i> , 2015, 115, 87-93.	1.3	19
113	Transperineal prostate biopsies for diagnosis of prostate cancer are well tolerated: a prospective study using patient-reported outcome measures. <i>Asian Journal of Andrology</i> , 2017, 19, 62.	0.8	21
114	Robotic assisted laparoscopic radical prostatectomy following transrectal compared to transperineal prostate biopsy: surgical, oncological and functional outcomes. <i>Minerva Urology and Nephrology</i> , 2016, 69, 85-92.	1.3	1
115	A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy. <i>BMC Urology</i> , 2016, 16, 39.	0.6	12
116	Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?. <i>Journal of Urology</i> , 2016, 196, 1069-1075.	0.2	37
117	Investigating the prostate specific antigen, body mass index and age relationship: is an age-adjusted BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , 2016, 27, 1465-1474.	0.8	17
118	High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. <i>Oncology Letters</i> , 2016, 11, 1375-1381.	0.8	11
119	Misclassification of outcome in case-control studies: Methods for sensitivity analysis. <i>Statistical Methods in Medical Research</i> , 2016, 25, 2377-2393.	0.7	23
120	The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies. <i>Journal of Urology</i> , 2016, 195, 1403-1408.	0.2	24
121	Global Hypomethylation (LINE-1) and Gene-Specific Hypermethylation (GSTP1) on Initial Negative Prostate Biopsy as Markers of Prostate Cancer on a Rebiopsy. <i>Clinical Cancer Research</i> , 2016, 22, 984-992.	3.2	22
122	Markov Decision Processes in Practice. <i>Profiles in Operations Research</i> , 2017, . .	0.3	40
123	MR/US Fusion Technology: What Makes It Tick?. <i>Current Urology Reports</i> , 2017, 18, 20.	1.0	5

#	ARTICLE	IF	CITATIONS
125	Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. <i>Radiology</i> , 2017, 285, 157-166.	3.6	66
126	The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naïve men. <i>Current Opinion in Urology</i> , 2017, 27, 488-494.	0.9	15
127	Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer. <i>Medical Decision Making</i> , 2017, 37, 815-826.	1.2	12
128	Markov Decision Processes for Screening and Treatment of Chronic Diseases. <i>Profiles in Operations Research</i> , 2017, , 189-222.	0.3	36
129	Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning. <i>Current Urology Reports</i> , 2017, 18, 93.	1.0	2
130	Pathological and oncological features of Korean prostate cancer patients eligible for active surveillance: analysis from the K-CaP registry. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 981-985.	0.6	9
131	Transrectal real-time tissue elastography targeted biopsy coupled with peak strain index improves the detection of clinically important prostate cancer. <i>Oncology Letters</i> , 2017, 14, 210-216.	0.8	8
132	Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. <i>Cancer Research</i> , 2017, 77, 355-365.	0.4	38
134	Application of ultrasound imaging biomarkers (HistoScanning [®]) improves staging reliability of prostate biopsies. <i>BMC Research Notes</i> , 2017, 10, 579.	0.6	1
135	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , 2018, 52, 99-105.	0.8	8
136	High-Frequency Quantitative Ultrasound for Imaging Prostate Cancer Using a Novel Micro-Ultrasound Scanner. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1341-1354.	0.7	58
137	Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. <i>BJU International</i> , 2018, 122, 50-58.	1.3	49
138	Feasibility study of MR-guided transgluteal targeted in-bore biopsy for suspicious lesions of the prostate at 3 Tesla using a freehand approach. <i>European Radiology</i> , 2018, 28, 2690-2699.	2.3	7
139	Internal Fusion: exact correlation of transrectal ultrasound images of the prostate by detailed landmarks over time for targeted biopsies or follow-up. <i>World Journal of Urology</i> , 2018, 36, 693-698.	1.2	6
140	Optimal healthcare decision making under multiple mathematical models: application in prostate cancer screening. <i>Health Care Management Science</i> , 2018, 21, 105-118.	1.5	24
141	Liquid Biopsy Potential Biomarkers in Prostate Cancer. <i>Diagnostics</i> , 2018, 8, 68.	1.3	9
142	Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis. <i>Cancer Cell International</i> , 2018, 18, 177.	1.8	37
143	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK. <i>BMJ Open</i> , 2018, 8, e024941.	0.8	14

#	ARTICLE	IF	CITATIONS
144	Prevalence and associated factors of incidentally diagnosed prostatic carcinoma among patients who had transurethral prostatectomy in Tanzania: a retrospective study. Ethiopian Journal of Health Sciences, 2018, 28, 11.	0.2	11
145	¹⁸ F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. Journal of Nuclear Medicine, 2019, 60, 1705-1712.	2.8	12
146	Implications from autopsy studies of latent prostate cancer. Nature Reviews Urology, 2020, 17, 428-429.	1.9	2
147	The characteristics and spatial distributions of prostate cancer in autopsy specimens. Prostate, 2021, 81, 135-141.	1.2	4
148	“More men die with prostate cancer than because of it” – an old adage that still holds true in the 21st century.. Cancer Treatment and Research Communications, 2021, 26, 100225.	0.7	11
149	Latent prostate cancer among Japanese males: a bibliometric study of autopsy reports from 1980–2016. Japanese Journal of Clinical Oncology, 2021, 51, 156-159.	0.6	0
150	Is there a clinical benefit from prostate cancer center certification? An evaluation of functional and oncologic outcomes from 22,649 radical prostatectomy patients. World Journal of Urology, 2021, 39, 5-10.	1.2	17
151	Deep Learning-Based Cancer Region Segmentation from H&E Slides for HPV-Related Oropharyngeal Squamous Cell Carcinomas. , 2021, , 137-147.		0
152	Impact of cancer screening on metastasis: A prostate cancer case study. Journal of Medical Screening, 2021, 28, 096914132198973.	1.1	0
153	Current Trends of Carcinoma: Experience of a Tertiary Care Cancer Center in North India. Cureus, 2021, 13, e15788.	0.2	1
154	Anterior and apical samplings during transperineal image-guided prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 5.e15-5.e21.	0.8	2
155	Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. Value in Health, 2021, 24, 1111-1117.	0.1	9
156	Rapid Tissue Donation (RTD) for Oncology Research. The International Library of Bioethics, 2021, , 1-17.	0.1	0
157	Global Trends of Latent Prostate Cancer in Autopsy Studies. Cancers, 2021, 13, 359.	1.7	24
158	“How to Make TRUS Better” HistoScanning-Guided Biopsies for Identification of Cancer Within the Prostate. , 2015, , 51-57.		1
159	Cancer Screening in the U.S. and Europe: Policies, Practices, and Trends in Cancer Incidence and Mortality. , 2013, , 125-154.		2
160	Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian Journal of Andrology, 2012, 14, 355-360.	0.8	23
161	The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. PLoS ONE, 2016, 11, e0154499.	1.1	64

#	ARTICLE	IF	CITATIONS
163	Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China. Asian Journal of Andrology, 2020, 22, 539.	0.8	7
164	Impact of PSA and DRE on Histologic Findings at Prostate Biopsy in Turkish Men Over 75 Years of Age. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6085-6088.	0.5	10
165	Prostate Cryoablation: Successful Therapy for Clinically Localized Prostate Cancer. , 2010, , 193-206.		0
166	Predicting Robotic Utilization in Urologic Disease: An Epidemiology-Based Model. , 2011, , 205-216.		0
167	Triggers for Intervention in Men on Surveillance. , 2012, , 55-65.		0
168	Transperineal Mapping Biopsy of the Prostate for Assessment of the Minimal Risk Patient. , 2013, , 277-284.		0
169	Characteristics of Prostate Cancers Missed by Biopsies: Evaluation of Cumulative Tumor Volume Missed According to Cancer True Prevalence. Open Journal of Urology, 2013, 03, 210-216.	0.0	0
170	Quantitative Ultrasound for Tissue-type Imaging of the Prostate: Implications for Planning and Guiding Biopsies and Delivering Focal Treatments. , 2013, , 171-192.		0
171	Magnetic Resonance Imaging in Prostate Cancer Diagnosis. , 2015, , 15-20.		0
172	Clinical Presentation, Diagnosis and Staging. , 2015, , 697-717.		1
173	Prostate Imaging. , 2015, , 635-654.		0
174	Les bases de données médicales et les innovations technologiques peuvent améliorer la pertinence du diagnostic précoce du cancer de la prostate. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1839-1852.	0.0	0
175	Assessing the diagnostic performance of systematic freehand precisionpoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 4.e9-4.e17.	0.8	0
177	Occult prostate cancer effects the results of case-control studies due to verification bias. Anticancer Research, 2008, 28, 3007-10.	0.5	7
179	The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Canadian Journal of Urology, 2008, 15, 3866-71.	0.0	265
180	Temporal trends and racial disparities in global prostate cancer prevalence. Canadian Journal of Urology, 2014, 21, 7496-506.	0.0	37
181	Safety and Diagnostic Yield of ⁶⁸ Ga Prostate-specific Membrane Antigen PET/CT-guided Robotic-assisted Transgluteal Prostatic Biopsy. Radiology, 2022, 303, 392-398.	3.6	14
182	Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate Cancer. European Urology Focus, 2022, , .	1.6	3

#	ARTICLE	IF	CITATIONS
183	Impact of mpMRI targeted biopsy on intraoperative nerve-sparing (NeuroSAFE) during robot-assisted laparoscopic radical prostatectomy. <i>Prostate</i> , 2022, 82, 493-501.	1.2	4
185	Optimization of Biomarker-Based Prostate Cancer Screening Policies. , 2022, , 141-158.		0
188	Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas. <i>JAMA Health Forum</i> , 2022, 3, e221116.	1.0	3
189	Using deep learning to detect patients at risk for prostate cancer despite benign biopsies. <i>Science</i> , 2022, 25, 104663.	1.9	5
190	Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 867-880.	1.0	3
191	Single-cell and WGCNA uncover a prognostic model and potential oncogenes in colorectal cancer. <i>Biological Procedures Online</i> , 2022, 24, .	1.4	7
192	Comparison of malignancy and spatial distribution between latent and clinical prostate cancer: an 8-year biopsy study. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	1